CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 
 

VIR's Revenue Growth by Quarter and Year

Vir Biotechnology Inc 's Revenue results by quarter and year




VIR Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 49.41 812.76 1.73 -1.40
III Quarter September 374.56 103.62 1.93 1.40
II Quarter June -40.63 177.07 66.99 0.00
I Quarter March 1,232.46 1.98 5.72 0.00
FY   1,615.80 1,095.43 76.37 0.00



VIR Revenue fourth quarter 2022 Y/Y Growth Comment
Vir Biotechnology Inc reported drop in Revenue in the fourth quarter 2022 by -93.92% to $ 49.41 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Vir Biotechnology Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 10436.45%.

Among companies who have reported fourth quarter 2022 results in the Biotechnology & Pharmaceuticals industry only one Company has achieved higher year on year Revenue results in the fourth quarter 2022. While Vir Biotechnology Inc ' s Revenue meltdown of -93.92% ranks overall at the positon no. 10 in the fourth quarter 2022.




VIR Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -93.92 % 46880.35 % - -
III Quarter September 261.47 % 5268.91 % 37.86 % -
II Quarter June - 164.32 % - -
I Quarter March 62145.45 % -65.38 % - -
FY   47.5 % 1334.37 % - -

Financial Statements
Vir Biotechnology Inc 's fourth quarter 2022 Revenue $ 49.41 millions VIR's Income Statement
Vir Biotechnology Inc 's fourth quarter 2021 Revenue $ 812.76 millions Quarterly VIR's Income Statement
New: More VIR's historic Revenue Growth >>


VIR Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December -86.81 % 684.37 % -10.36 % -
III Quarter September - -41.48 % -97.12 % -
II Quarter June - 8842.93 % 1071.15 % -
I Quarter March 51.64 % 14.45 % - -
FY (Year on Year)   47.5 % 1334.37 % - -




Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #2
Healthcare Sector #4
Overall #10

Revenue Y/Y Growth Statistics
High Average Low
46771.68 % 10436.45 % -65.44 %
(Dec 31 2021)   (Mar 31 2021)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #2
Healthcare Sector #4
Overall #10
Revenue Y/Y Growth Statistics
High Average Low
46771.68 % 10436.45 % -65.44 %
(Dec 31 2021)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Vir Biotechnology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
8860.93 % 1497.45 % -97.12 %
(Jun 30 2021)  


VIR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Vir Biotechnology Inc realized fall in Revenue from the third quarter by -86.81% to $ 49.41 millions, from $ 374.56 millions declared a quarter before.

Albeit cyclical circumstance commonly elevate IV. Quarter 2022 Revenue, this plainly has not been sufficient to salvage Biotechnology & Pharmaceuticals's company IV. Quarter 2022 achievement, Amy Davis, an industry contributor allocated in Dallas said and continued that average sequential Revenue growth is at 1497.45% for VIR.

Within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 57.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #29
Overall #57
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #29
Overall #57
Revenue Q/Q Growth Statistics
High Average Low
8860.93 % 1497.45 % -97.12 %
(Jun 30 2021)  


VIR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Vir Biotechnology Inc reported fall in Revenue from the previous quarter by -86.81% to $ 49.41 millions, from $ 374.56 millions declared a quarter before.

Albeit cyclical circumstance usually energize IV. Quarter 2022 Revenue, it simply could not be enough to recover Biotechnology & Pharmaceuticals's company IV. Quarter performance, Amy Davis, an industry contributor allocated in Dallas pointed out.

Within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Vir Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 57.


Vir Biotechnology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 1,615.80 $ 2,379.14 $ 2,108.20 $ 2,325.90 $ 1,095.42
Y / Y Revenue Growth (TTM) 47.51 % 736.57 % 1053.88 % 3102.57 % 1334.39 %
Year on Year Revenue Growth Overall Ranking # 33 # 134 # 199 # 0 # 0
Seqeuential Revenue Change (TTM) -32.08 % 12.85 % -9.36 % 112.33 % 285.18 %
Seq. Revenue Growth (TTM) Overall Ranking # 34 # 1907 # 2461 # 2334 # 2682




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Vir Biotechnology Inc 's cumulative twelve months Revenue were $ 1,616 millions, company would post below average annual Revenue growth of 285.18% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Vir Biotechnology Inc 's Revenue growth from the 374.56% growth in Sep 30 2022.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 33, from total ranking in previous quarter at 134.

Revenue TTM Q/Q Growth Statistics
High Average Low
285.18 %
82.08 %
-4.9 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 12
Overall # 33

Revenue TTM Y/Y Growth Statistics
High Average Low
1334.39 %
591.35 %
151.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 10
S&P 500 # 34
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Vir Biotechnology Inc 's cumulative twelve months Revenue were $ 1,616 millions, company would post below average annual Revenue growth of 151.29% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Vir Biotechnology Inc 's Revenue growth from the 374.56% growth in Sep 30 2022.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 33, from total ranking in previous quarter at 134.

Revenue TTM Q/Q Growth Statistics
High Average Low
285.18 %
82.08 %
-4.9 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 12
Overall # 33

Revenue TTM Y/Y Growth Statistics
High Average Low
1334.39 %
591.35 %
151.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 10
S&P 500 # 34




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VIR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for VIR's Competitors
Revenue Growth for Vir Biotechnology Inc 's Suppliers
Revenue Growth for VIR's Customers

You may also want to know
VIR's Annual Growth Rates VIR's Profitability Ratios VIR's Asset Turnover Ratio VIR's Dividend Growth
VIR's Roe VIR's Valuation Ratios VIR's Financial Strength Ratios VIR's Dividend Payout Ratio
VIR's Roa VIR's Inventory Turnover Ratio VIR's Growth Rates VIR's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
National Research Corporation-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd -0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc -1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Uphealth Inc -2.20%$ -2.203 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions
Community Health Systems Inc -2.85%$ -2.846 millions
Invitae Corporation-2.91%$ -2.908 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com